Loïc Perchenet
Actelion
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Loïc Perchenet as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 03:36 UTC. Open this list on ClinicalTrials.gov
- Ph4NCT02382016 · PORtopulmonary Hypertension Treatment wIth maCitentan - a randOmized Clinical TrialActelion · completed · Portopulmonary Hypertension · study director
- Ph4NCT02310672 · REPAIR: Right vEntricular Remodeling in Pulmonary ArterIal hypeRtensionActelion · completed · Pulmonary Arterial Hypertension · study director
- Ph3NCT02112487 · Extension of the Psychometric Validation Study ORCHESTRA in Patients With PAHActelion · completed · Pulmonary Arterial Hypertension · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 03:36 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 03:36 UTC. The ranking covers the 200 most relevant of 13 PubMed records, and a shared surname and initials can bring in a namesake. All 13 on PubMed
- Macitentan and morbidity and mortality in pulmonary arterial hypertension.N Engl J Med · 20131,077 citationsRCR 37.7
- 434 citationsRCR 12.6
- Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial.Eur Respir J · 2013216 citationsRCR 7.1
- Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension.J Am Coll Cardiol · 2021141 citationsRCR 9.7
- Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality.J Am Coll Cardiol · 201897 citationsRCR 4.3
- 64 citationsRCR 2.7
- Early worsening heart failure in patients admitted for acute heart failure: time course, hemodynamic predictors, and outcome.J Card Fail · 200957 citationsRCR 1.6
- The hemodynamic and neurohormonal effects of low doses of tezosentan (an endothelin A/B receptor antagonist) in patients with acute heart failure.Eur J Heart Fail · 200452 citationsRCR 1.3
- 46 citationsRCR 2.0
- 40 citationsRCR 1.9